Imatinib production process
    2.
    发明授权
    Imatinib production process 失效
    伊马替尼生产过程

    公开(公告)号:US07550591B2

    公开(公告)日:2009-06-23

    申请号:US11743520

    申请日:2007-05-02

    IPC分类号: C07D401/14

    CPC分类号: C07D401/04 C07D295/155

    摘要: Provided is a process for producing imatinib and salts thereof, e.g., imatinib mesylate. The process includes reacting 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid with N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine in the presence of a carboxylic acid coupling reagent, to produce imatinib, and optionally converting the imatinib into a salt.

    摘要翻译: 提供生产伊马替尼及其盐的方法,例如甲磺酸伊马替尼。 该方法包括使4-(4-甲基 - 哌嗪-1-基甲基) - 苯甲酸与N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺在 羧酸偶联试剂,以产生伊马替尼,以及任选地将伊马替尼转化成盐。

    Metasurface skin cloak
    5.
    发明授权

    公开(公告)号:US10883799B1

    公开(公告)日:2021-01-05

    申请号:US14999918

    申请日:2016-12-13

    IPC分类号: H01Q15/02 F41H3/02 H01Q17/00

    摘要: This disclosure provides systems, methods, and devices related to a metasurface skin cloak. In one aspect, a metasurface skin cloak includes a dielectric layer and a plurality of blocks disposed on the dielectric layer. The dielectric layer is disposed over a surface including a feature on the surface. Each block of the plurality of blocks has a shape that is symmetric about two perpendicular axes. The metasurface skin can render the feature on the surface not optically detectable.

    NANOPORE DEVICES FOR SENSING BIOMOLECULES
    6.
    发明申请

    公开(公告)号:US20180280968A1

    公开(公告)日:2018-10-04

    申请号:US15945717

    申请日:2018-04-04

    摘要: The present disclosure provides chips, devices and methods for sequencing a biomolecule. The biomolecule may be DNA, RNA. a protein, or a peptide. The chip comprises a substrate; a first and second fluid chamber; fluid channels connecting the first and second fluid chamber; a first and second electrode disposed on opposing sides of the central fluid channel and having a nanogap therebetween, wherein the width of the nanogap is modulated by confined electrochemical deposition; and a passivation layer disposed on top of the first and second electrodes and the fluid channel.

    Federation of multi-level master data management systems
    9.
    发明授权
    Federation of multi-level master data management systems 失效
    多级主数据管理系统联合会

    公开(公告)号:US08635249B2

    公开(公告)日:2014-01-21

    申请号:US13117370

    申请日:2011-05-27

    IPC分类号: G06F17/30

    CPC分类号: G06F17/30286 G06F17/30566

    摘要: Federating multiple-level master data management systems may include a first set of master data management nodes having one or more common characteristics. A first group master data management node may be assigned to centrally manage the first set of master data management nodes, the first group master data management node maintaining master data management functionalities at a group level and providing a single logical view of master data to the first set of master data management nodes. Each master data management node in the first set has data access link with the first group master data management node based on implementation style of said each master data management node.

    摘要翻译: 联合多级主数据管理系统可以包括具有一个或多个共同特征的第一组主数据管理节点。 可以分配第一组主数据管理节点以集中管理第一组主数据管理节点,第一组主数据管理节点维护组级别的主数据管理功能,并将主数据的单个逻辑视图提供给第一组主数据管理节点 主数据管理节点集。 基于所述每个主数据管理节点的实现风格,第一组中的每个主数据管理节点与第一组主数据管理节点具有数据访问链路。

    S-5-SUBSTITUENT-N-2'-(THIOPHENE-2-YL)ETHYL-TETRALIN-2-AMINE OR CHIRAL ACID SALTS THEREOF AND USE FOR PREPARING ROTIGOTINE
    10.
    发明申请
    S-5-SUBSTITUENT-N-2'-(THIOPHENE-2-YL)ETHYL-TETRALIN-2-AMINE OR CHIRAL ACID SALTS THEREOF AND USE FOR PREPARING ROTIGOTINE 有权
    S-5-替代N-2' - (噻吩-2-基)乙基 - 四环素-2-胺或其酸性酸盐及其制备ROTIGOTINE的用途

    公开(公告)号:US20130046100A1

    公开(公告)日:2013-02-21

    申请号:US13394614

    申请日:2010-09-07

    IPC分类号: C07D333/20 C07D333/22

    CPC分类号: C07D333/20 C07B57/00

    摘要: The chiral compound S-5-substituted-N-2′-(thienyl-2-yl-)ethyl-tetralin-2-amine or its chiral acid salts and preparation method thereof are disclosed, and the method for preparing Rotigotine by using the chiral compound is also disclosed. Racemic 5-substituted-N-2′-(thien-2-yl-)ethyl-tetralin-2-amine (compound 1) is resolved by using a conventional chiral acid to obtain an optically pure chiral acid salt of S-5-substituted-N-2′-(thien-2-yl-)ethyl-tetralin-2-amine, which is then dissociated to obtain S-5-substituted-N-2′-(thien-2-yl-)ethyl-tetralin-2-amine (compound 2). The compound 2 or chiral acid salt thereof is alkylated and deprotected to produce rotigotine (compound 5).

    摘要翻译: 公开了手性化合物S-5-取代-N-2' - (噻吩基-2-基) - 乙基 - 四氢化萘-2-胺或其手性酸盐及其制备方法, 还公开了手性化合物。 通过使用常规的手性酸来拆分外消旋的5-取代的N-2' - (噻吩-2-基)乙基 - 四氢化萘-2-胺(化合物1),得到光学纯的手性酸S-5- 取代的N-2' - (噻吩-2-基)乙基 - 四氢化萘-2-胺,然后将其解离得到S-5-取代的N-2' - (噻吩-2-基) 四氢化萘-2-胺(化合物2)。 将化合物2或其手性酸式盐进行烷基化和脱保护,得到罗替戈汀(化合物5)。